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Abstract 
Novel cell therapies derived from human T lymphocytes are exhibiting enormous potential in 
early phase clinical trials in patients with haematological malignancies. Ex-vivo modification 
of T cells is currently limited to a small number of centres with the required infrastructure 
and expertise. The process requires isolation, activation, transduction, expansion and 
cryopreservation steps. To simplify procedures and widen applicability for clinical therapies, 
automation of these procedures is being developed. The CliniMACS Prodigy (Miltenyi 
Biotec) has recently been adapted for lentiviral transduction of T cells and here we analyse 
the feasibility of a clinically compliant T-cell engineering process for the manufacture of 
T cells encoding chimeric antigen receptors (CAR) for CD19 (CAR19), a widely targeted 
antigen in B-cell malignancies. Using a closed, single-use tubing set we processed 
mononuclear cells from fresh or frozen leukapheresis harvests collected from healthy 
volunteer donors. Cells were phenotyped and subjected to automated processing and 
activation using TransAct, a polymeric nanomatrix activation reagent incorporating 
CD3/CD28-specific antibodies. Cells were then transduced and expanded in the CentriCult-
Unit of the tubing set, under stabilised culture conditions with automated feeding and media 
exchange. The process was continuously monitored to determine kinetics of expansion, 
transduction efficiency and the phenotype of the engineered cells in comparison to small-
scale transductions run in parallel. We found that transduction efficiencies, phenotype and 
function of CAR19 T cells were comparable to existing procedures and overall T-cell yields 
sufficient for anticipated therapeutic dosing. The automation of closed-system T-cell 
engineering should improve dissemination of emerging immunotherapies and greatly widen 
applicability. 
(250 words) 
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Optional:  Highlights (3-5 bullet points, max 85 characters per point incl space) 
- Demonstration of feasibility of CliniMACS Prodigy for T cell transduction 
- Successful automated generation of CD19-CAR+ T cells in clinically relevant doses 
- Confirmation of in vitro and in vivo efficacy of automatically generated product  
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Introduction 
Genetically modified T cells are exhibiting enormous potential for the treatment of relapsed 
and refractory haematopoietic malignancies. In particular, CD19-positive B-cell malignancies 
such as acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL) or B 
cell non-Hodgkin lymphomas (NHL) have been shown to be an excellent target for adoptive 
immunotherapy with T cells expressing CD19-specific chimeric antigen receptors (CARs) [1-
3]. These CARs comprise fusions of antibody derived antigen-recognition domains and 
various T-cell receptor (TCR) signalling domains, capable of inducing T-cell activation, 
proliferation and effector functions upon antigen recognition. To achieve long-lasting anti-
tumour effects CAR-T cells are primarily generated by lenti- or γ-retroviral vector mediated 
transduction. Although these procedures are well established, clinical application is limited to 
a small number of manufacturing facilities with the required infrastructure, containment 
approval and expertise for Good Manufacturing Practice (GMP). The manufacturing of 
genetically engineered T cells is a complex process which can be separated into the following 
steps (Figure 1A): Isolation of mononuclear cells from human subjects, activation of T cells 
to induce mitosis for enhanced susceptibility for viral transduction, expansion of cells 
following transduction and finally the harvest of the product followed by formulation and/or 
cryopreservation. Various culture vessels, including G-Rex flasks, cell differentiation bags 
and bioreactors have proven suitability for T-cell manufacturing [4-6]. Current procedures 
involve a variety of hands-on steps and transfer of cells between cultivation vessels, each 
bearing the risk of contamination, human errors and cell loss. To simplify the protocol and 
minimise potential risks during the process, the CliniMACS Prodigy [7] has been adapted to 
automate clinical-scale manufacturing of cell products  [8-10]. This platform allows for 
magnetic bead based cell separation followed by activation, transduction, multiple media-
exchanges, and washing steps with a single-use, closed tubing-system (Figure 1A, Figure 
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1B). Programming flexibility incorporates an  “activity matrix” that is user-defined and 
determines the chronological order of different cultivation steps, feed schedules and duration 
of culture. It is highly adaptable and can be changed during the process to adjust to individual 
sample requirements. Here we demonstrate the feasibility of the automated T-cell 
transduction process on the CliniMACS Prodigy and evaluate the generated T-cell products 
on a phenotypic and functional level (in vitro and in vivo) alongside manually processed 
cells.   
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Materials and Methods 
Automated T-cell transduction (CliniMACS Prodigy) 
Automated T-cell transduction (TCT) was performed on the CliniMACS Prodigy using the 
Tubing Set TS520 and the T-cell transduction process. Where not specified otherwise, 
reagents and materials were obtained from Miltenyi Biotec. An overview of the general 
procedure is depicted in Figure 1D. In brief, leukapheresis from healthy donors were either 
obtained fresh (donor #15-01 and #15-03 and #15-GMP-03) or frozen (#15-04/6, #15-07, 
#15-GMP-01 and #15-GMP-02) (Caltag). Frozen cells were thawed on d-1 of the procedure, 
washed with TexMACS GMP Medium supplemented with 10%HS (GemCell Human Serum 
AB, premium grade (Seralab)) in the presence of at least 50U/ml Benzonase-Nuclease 
(Sigma-Aldrich) and rested overnight at 37°C in TexMACS, 3%HS at a density of 2x10
6
/ml. 
Fresh cells were washed in PBS to remove residual donor-serum. Cells were transferred into 
a 150ml Transfer Bag and attached to the TS520 by sterile welding. Cultivation was initiated 
with a SYSMEX based cell count of 7.45x10
7–1x108 lymphocytes in a total volume of 70ml 
TexMACS, 3%HS + 20ng/ml MACS GMP Human Recombinant IL-2 in the CentriCult-Unit. 
Cells were activated with MACS GMP TransAct CD3/CD28 Kit at a final dilution of 1:200 
(CD3 Reagent) and 1:400 (CD28 Reagent. Cells were transduced on d1 or d2 using an MOI 
of 5 with a self-inactivating third generation lentiviral vector encoding a CAR specific for 
CD19, under the control of EF1 internal promoter and including a mutated woodchuck post-
regulatory element (WPRE) and HIV central polypurine tract (cPPT). Vector was 
pseudotyped with vesicular stomatitis virus (VSV) and concentrated by ultracentrifugation. 
Titres were calculated by flow cytometric assessment of 293T cells and Jurkat T cells 
transduced with serial vector dilutions. GMP vector stocks were subjected to additional 
release assays as described previously [11]. The vector was diluted in 10mls of media in a 
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150ml transfer bag which was then attached to the CliniMACS Prodigy by sterile welding. 
The vector was automatically transferred in the culture chamber and the vector bag was 
further rinsed with 20ml of media to bring the total culture volume to 100ml.  Sampling was 
performed daily for monitoring purposes starting at d3. Monitoring included SYSMEX-based 
cell count and flow-cytometry Residual TransAct was removed by an automated “culture 
wash” on d4 or d5 followed by automated activation of the shaker (type 1). More vigorous 
shaking was initiated depending on cell density (type 2: density > 3x10
6
/ml or type 3: density 
> 4x10
6
/ml). For the final harvest, cells were automatically formulated in 0.9% Sodium-
Chloride solution or CliniMACS PBS/EDTA supplemented with 0.5% HAS (Zenalb20 – Bio 
Product Laboratory) and transferred into a bag. 
Cell culture 
For each process performed on the CliniMACS Prodigy, cells from the same donor were 
activated, transduced and expanded on a reduced scale for comparison.. For each condition, 
4x10
6
 washed lymphocytes were either re-suspended to 1x10
6
/ml in TexMACS 3%HS + 
20ng/ml IL-2 and activated with TransAct as per Prodigy protocol, or re-suspended in X-
Vivo 15 (Lonza) 5% HS + 20ng/ml IL-2 and activated at a 1:1 ratio with human T-Activator 
CD3/CD28 Dynabeads (Dynal). Cells were cultured in 48-well plates at a density of 1x10
6
/ml 
in a total volume of 700µl,a 100 fold reduction of culture conditions compared to the 
CliniMACS Prodigy. On d1 or d2 cells were divided into untransduced controls or transduced 
with CD19-CAR vector at an MOI of 5.The vector was added to each well in a total volume 
of 300μl to have a total culture volume of 1ml. To mimic the culture wash on d4 or d5, 
TransAct activated cells were washed once with TexMACS by centrifugation cell culture 
media and re-suspended in 40mls fresh TexMACS 3%HS + 20ng/ml IL-2 and transferred to a 
G-Rex 10 (Wilson Wolf Manufacturing) for expansion mimicking the prodigy culture 
chamber. Similarly, Dynabead activated cells were harvested, topped up to 40mls of X-Vivo 
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3%HS + 20ng/ml IL-2 and transferred to a G-Rex 10. Small scale activated cells were 
harvested at the same time point as cells on the CliniMACS Prodigy and cryopreserved. 
SupT1 cells and CD19+ SupT1 cells, that had previously been engineered to express 
recombinant CD19, were used for further functional studies and were cultured in RPMI 10% 
FCS. This cell line was authenticated using the ATCC Cell Line Authentication Service.   
 
Flow Cytometry 
To phenotype expanded cells, cells were stained with the following primary antibodies (from 
Miltenyi Biotec unless otherwise stated) CD3-PE Vio770, CD4-Vio Blue, CD8-PE, CD45-
VioGreen, CD45RA – PE Vio770, CCR7-PE, CD62L-APCCy7 (Biolegend), CD95-BV421 
(Biolegend), CD14-APC, CD20-APC Vio770, CD56-PE Vio770. To assess the efficiency of 
CD19-CAR transduction, cells were stained using a Biotin-SP (long spacer) AffiniPure 
F(ab') Fragment Goat Anti-Mouse IgG, F(ab') Fragment Specific antibody 
(Jackson Immunoresearch) followed by Streptavidin-APC or Streptavidin-FITC (Biolegend). 
Cells were acquired on a 4-laser BD LSRII and FACS analysis performed using FlowJo v10. 
 
Cytokine secretion assay  
CD19-CAR transduced cells were thawed, washed and re-suspended in RPMI 10% FCS at a 
concentration of 1x10
6
/ml CAR19+ cells. CD19- SupT1 cells and CD19+ SupT1 cells were 
counted and also adjusted to a concentration of 1x10
6
/ml. Cells were mixed at a 1:1 ratio in 
24 well tissue culture plates and incubated at 37°C. After 24h supernatants were harvested 
and stored at -80˚C. Levels of cytokine in the stored supernatants were quantified using the 
TH1/TH2/TH17 cytometric bead array kit (BD Biosciences) as per the manufacturers’ 
protocol.  
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Cytotoxicity Assay 
Cytotoxic activity of CAR19-cells was assessed by chromium (
51
Cr) release assay. For this 
5x10
3
 
51
Cr-labeled CD19-positive SupT1-target cells were incubated with CD56-depleted 
(CD56-MicroBeads, Miltenyi Biotec, 130-050-401) effector cells at increasing effector-to-
target ratios (E:T ratios) in 96-well microplates for 4h at 37°C and 
51
Cr-release measured in a 
microplate scintillation counter.  
 
Anti-tumour effectivity in vivo  
NSG mice injected with 2.5x10
5
 CD19+ Raji tumour cells expressing Luciferase were treated 
on d2 with 4x10
6
 prodigy transduced cells (CAR+) or a similar number of non-transduced 
(NT) cells expanded in a G-Rex flask. In vivo imaging of bioluminescence was performed on 
d1, d6, d9 and d13 (Figure 4A). Bone marrow samples for flow cytometric analysis were 
prepared by lysing of the red blood cells followed by a blocking step using FcR Blocking 
reagent, mouse (Miltenyi Biotec) and supernatant from the 2.4G2 hybridoma. Samples were 
stained with CD4-BV650, CD8-PE-CY7, CD20-PerCPcy5.5, CD19-APC and CD38-
eFluour450. Samples were fixed overnight in 0.2% PFA prior to flow cytometry acquisition 
on a BD LSR-Fortessa cytometer. 
Statistics 
An unpaired Student’s t test was used to assess the significance of activating cells with 
Dynabeads in XV5% or with TransAct in TM3%. For comparisons of cells produced in 
automated or manual processes a one way analysis of variance with Bonferroni’s post-test 
was used. All statistical analysis was performed using GraphPad Prism software version 5.01.  
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Results 
Comparison of activation reagents and media for automated T-cell transduction 
Most existing T-cell manufacturing protocols use either soluble or magnetic-bead (Dynabead) 
bound anti-CD3/CD28-antibodies in media such as X-Vivo10 or 15 supplemented with 
interleukin-2 (IL2). In contrast, the automated T cell transduction TCT protocol for the 
CliniMACS Prodigy adopts TransAct, a soluble, colloidal reagent with covalently attached 
anti-CD3/CD28-antibodies [12], in combination with TexMACS GMP medium. TransAct 
can be removed from the culture by washing cells and obviates the need for a bead-removal 
step required for CD3/CD28-Dynabeads. To test the suitability of these reagents for 
expanding and transducing T cells with 3
rd
 generation lentiviral vector encoding a CAR19 
receptor with 41BB and CD3 activation domains, small-scale transductions of PBMCs 
activated with TransAct were performed alongside standard conditions using CD3/CD28 
Dynabeads. Cell expansion, phenotype and transduction efficiency were evaluated. As 
depicted in Figure 2A, cells activated with Dynabeads showed a significantly higher 
expansion rate (mean fold expansion 63.6±21.3) compared to TransAct-activated cells 
(37.7±14.9) (P<0.04). However, transduction efficiency was greater for cells activated with 
TransAct compared to cells activated with Dynabeads (P<0.03) (Figure 2B) and cells 
activated with TransAct showed increased transduction efficiency of CD8+ T cells in 
comparison to cells activated with Dynabeads (Figure 2C). The increased transduction 
efficiency of cells activated with TransAct led to a comparable yield of CD19-CAR+ T cell 
between the two activation conditions (Figure 2D). Overall, these validations confirmed the 
potential of TransAct and TexMACS to support a sufficient yield of CAR19 engineered cells 
for clinical therapies.  
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Automated T-cell transduction using CliniMACS Prodigy  
To validate the automated TCT protocol on the CliniMACS Prodigy, large scale experiments 
were performed using either cryopreserved or fresh (steady-state) leukapheresis (Fig 1C) and 
the Tubing Set TS520. Transduction was performed with vector added by sterile welding of 
the supply bag to access tubing. In comparison to conventional manufacturing processes 
using the WAVE bioreactor, which can require over 24 hours of ‘hand-on’ time,  operator 
time was greatly reduced using the CliniMACS Prodigy (Table S1). The following 
parameters were assessed: expansion rate, transduction efficiency, viability, purity, immuno-
phenotype and functionality. Small-scale controls with either TransAct/TexMACS 
(TransAct) or Dynabeads/X-vivo (Dynabead) were run in parallel. 
Expansion and transduction efficiency of T cells using the CliniMACS Prodigy 
The expansion of lymphocytes in the CliniMACS Prodigy ranged from 5.4x – 28.4x (mean 
16.2x±7.9x) in cultures of 8-10 days (Fig.2A) and was comparable to expansion achieved in 
small scale controls on the same donors (Fig.2B; TransAct%: 18.1x ± 5.6x, Dynabead: 22.3 ± 
12.2x). This resulted in an average yield of 15.8 x 10
8
 total lymphocytes from the Prodigy 
(range: 4 – 23.2 x 108, also compare Table 1) from starting numbers of 0.7 - 1.2 x 108 (mean 
0.95 x 10
8 
± 0.1). Suboptimal feeding of cells during the expansion phase may have 
contributed to lower yields in 15-01 and 15-03 (Figure 3A) and increasing the volume of 
media exchange in subsequent runs seem to have supported greater cell expansion. In eight 
scaled productions, transduction averaged 47.6 ± 14.9% CAR19-positive T cells (range: 23.9 
- 66.4%, Figure 2C and Table 1). In small scale comparisons transduction efficiency was 
comparable for TransAct activated cells (Figure3D, TransAct: 51.8% ± 22.3% CAR19-
positive) but lower for Dynabead-activated cells (Figure 3D, Dynabead: 29.5% ± 14.1% 
CAR19-positive), confirming the results shown in Figure 2B. Thus, although the expansion 
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of Dynabead-activated cells was greater, the overall yield of CAR19+ T cells was similar as 
with TransAct and the automatically processed CliniMACS Prodigy product.  
Phenotype and purity of final cell product 
Cellular composition was analysed by flow cytometry for the presence of CD45+ 
lymphocytes, CD3+ T cells, CD14+ Monocytes, CD20+ B cells, CD3-CD56+ NK cells and 
CD3+CD56+ NKT cells. There was no significant difference in the phenotype of expanded 
cells in the automated or manual processes (Figure 4A) and over eight runs a mean CD3 T-
cell purity of 92.3% was achieved in the CliniMACS Prodigy compared to 96.7% (TransAct) 
and 98.0% (Dynabead) small scale controls. In runs 15-01 and 15-GMP-03 expansion of NK 
cells was detected (18.3% and 15.1%, respectively) in the automated compared to the manual 
processes. Interestingly, cells expanded in the CliniMACS Prodigy or in small scale controls 
with TransAct, had a greater percentage (49%) of CD8+ T cells in the final product compared 
to cells expanded in small scale controls with Dynabead (36%) although this difference did 
not reach significance in this limited number of experiments (Figure 4B). Possible T-cell 
exhaustion after ex vivo activation and expansion was determined by the expression of PD-1, 
a marker of reduced T-cell longevity [13]. The expression of PD-1 did not differ significantly 
in cells expanded in the CliniMACS Prodigy or in small scale comparison experiments 
(p=0.31), although there was a trend towards higher PD-1 expression in cells activated with 
TransAct in the latter (Figure 4C). In addition, immunophenotyping of cells expanded in the 
CliniMACS Prodigy was performed to further characterise memory T cell subpopulations. In 
order to generate a long-lasting immune response towards the target, memory T cells are 
thought to be the optimal target for adoptive immunotherapy [14]. Flow cytometric analysis 
for relevant surface markers was performed as shown and revealed that the majority of cells 
exhibited a memory phenotype, most being of either a central memory phenotype (TCM 
CD45-CD62L+) or stem cell memory phenotype (TSCM CD45+CD62L+CD95+) (Figure 4D 
Automated T cell transduction for GMP-manufacturing   
 
14 
 
and S1) (TCM+TSCM = 82.4% ±7.9%). The proportion of TCM and TSCM populations was 
comparable between cells expanded in the CliniMACS Prodigy or in small scale controls 
(TCM+TSCM for TransAct = 80.4% ± 9.6% and Dynabead = 70.4% ± 21.6). Moreover the 
memory phenotype of cells that were transduced with CD19-CAR were comparable to the 
phenotype of cells not expressing CD19-CAR in the same culture (Figure S2). 
Functional analysis of manufactured CD19-CAR T cells in vitro 
The final verification of the automated T cell transduction process was to assess whether the 
automated expanded CAR19 T cells retained the ability to respond to CD19-expressing target 
cells. To do so, co-cultures were performed with T cells and CD19-expressing SupT1 cells. 
CAR19+ cells co-cultured with CD19+ SupT1 cells secreted pro-inflammatory cytokines 
IFN-γ and TNF-α in response to their target antigen whereas cytokine secretion was not 
initiated upon co-culture with CD19- SupT1 cells (Figure 4E and S3). Cells expanded in the 
CliniMACS Prodigy produced less IFN-γ in response to CD19+ cells compared to cells 
expanded with TransAct in small scale controls (P<0.002). Secretion of of TNF-α and IL-2 
compared to both Dynabead and TransAct small scale controls was also lower, but did not 
reach significance. Importantly, CAR19 T cells generated in either manner did not produce 
regulatory cytokine IL-10 and produced cytokines associated with an effector TH1 phenotype 
and not those associated with either a TH2 or TH17 phenotype [15]. Furthermore, in a 
51
Cr-
release assay, the automated expanded CAR19+ T cells demonstrated specific lysis of CD19 
expressing SupT1 target cells (Figure 4F, and Supplementary Figure S4 for CD19 negative 
SupT1-controls). To assess cytotoxicity purely of expanded CAR19 T cells, the assay was 
performed on NK cell depleted, cryopreserved cells. Together, our data verify the 
functionality and specificity of automatically manufactured T cells.  
Anti-tumour activity of manufactured CD19-CAR T cells in vivo 
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In vivo efficacy of CD19-CAR engineered T cells was assessed in a human:murine tumour 
model. Immunodeficient NSG recipients were injected via tail vein with CD19 positive / 
luciferase expressing Raji cells two days before inoculation with control or CD19-CAR 
engineered T cells (Figure 5A). Upon in vivo imaging, mice that had received CD19-CAR 
expressing T cells exhibited tumour clearance by 11 days (representative images in Figure 5, 
full data set in Figure S5). Tumour clearance was not observed in control mice treated with 
PBS or NT T cells. Furthermore, absence of Raji populations was confirmed by flow 
cytometric analysis of the bone marrow in mice treated with automatically manufactured 
CD19-CAR T cells and in contrast to control treated mice (Figure S6).  
Discussion 
Wider application of adoptive T-cell therapies has been limited by the complexity of 
manufacturing processes and access to the required infrastructure and expertise. In this report 
on automated T cell processing on the CliniMACS Prodigy for the generation of CD19-CAR 
T cells we show that automated manufacturing of T cells, including cell-preparation, 
activation, transduction using lentiviral vectors, expansion and formulation, using the TCT-
program is practicable and adaptable. The majority of CAR19 T cells expanded in the 
CliniMACS Prodigy exhibited T stem cell memory (TSCM) and T central memory (TCM) T-
cell phenotypes, with high expression of CD45RA and CD62L. These are attractive 
phenotypes for adoptive immunotherapy approaches as less differentiated cells might 
improve therapeutic responses [16]. Although T effector memory cells (TEM) show higher 
cytolytic activity, TCM show a greater capacity to persist after adoptive transfer and are 
believed to further differentiate in vivo to support anti-tumour function [17]. In addition, the 
automatically generated CD19-CAR T cells functioned in an antigen specific manner and 
showed specific cytokine release, cytolytic activity upon incubation with CD19 SupT1 target 
cells and anti-tumour activity in a CD19+ humanised tumour mouse model. Elevations of 
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IFNγ following engagement of CD19-specific cytotoxic T cells produced by CAR T cells 
were as anticipated [14] but found to be lower in Prodigy manufactured cells compared to 
smaller scale controls. 
Importantly, the final T cell specifications were similar to products manufactured for CAR19- 
using already established clinical processes (defined as: >10% CAR19+, >70% viability and 
no growth in sterility tests). Moreover, yields of CAR19-positive T cells generated with the 
CliniMACS Prodigy (7.9x10
8 
± 4.0 CAR+ cells, Table 1) were comparable to previous 
validations procedures using a WAVE bioreactor preformed in our GMP facility (3.8x10
8
 ± 
4.5 CAR19+ cells, data not shown) and published yields reported in a clinical study for the 
treatment of ALL with a CD19-CAR T cell product, CTL019 (yield: 2.71x10
8
 ± 2.61 
CTL019 cells) [2].  
The present study shows the effectiveness of the automation of T-cell manufacturing for 
CAR T cell immunotherapy. Using the CliniMACS Prodigy, clinically relevant therapeutic 
doses of CD19-CAR T cells could be generated with minimal manipulation and a reduction 
in staff time compared to current T-cell processing protocols (Table S1). In the first instance 
the procedures have been adopted for the transduction of healthy donor T cells for 
programmed donor lymphocyte infusions in patients undergoing allo-SCT. Additional pre-
selection steps to enrich particular T cell subsets, or post transduction enrichment procedures 
could be incorporated with relative ease. Currently the TCT program is most suitable for high 
titre lentiviral vectors and development of transduction processes with γ-retroviral vectors 
where co-localisation agents such as Retronectin is usually required, is underway.  Wider 
applications for T cell and stem cell engineering procedures are foreseen and rapid 
dissemination of the technology to centres already using CliniMACS platform should help 
widen access and applicability. 
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Figures 
Figure 1. The T-cell transduction program on the CliniMACS Prodigy. (A) Overview of 
T-cell manufacturing processes and all equipment required. Left: Established protocol 
applied in clinical studies for adoptive immunotherapies. Right: Simplified procedure using 
the CliniMACS Prodigy where the majority of processing steps take place using the 
CliniMACS prodigy. Adapted from Kaiser et al [18]./Zhan et al.[5] (B) Tubing Set TS520. 
Single-use, closed tubing set allows for sterile handling of cell products in a single container. 
The CentriCult-Unit is an integral part of the tubing set and enables cultivation with stable 
temperature, gas-mix and the possibility to wash cells during the procedure without removing 
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them from the device. Reagents, cells and media are connected to the TS520 by sterile 
welding without compromising sterility of the procedure. The numbers are representative of 
the numbered valves on the CliniMACS prodigy (C) Example for TCT-work flow. Upon 
starting the process, an “activity matrix” is programmed by the user by the addition of 
different activity modules (Transduction, Feed, etc.) into the matrix. This makes the TCT 
process adaptable depending on the cell source, vector-type and desired expansion period for 
the respective product. There are three types of shaking that can be implemented in the 
Centricult unit depending on the cell concentration in the chamber : Type 1 - 100RPM, one 
direction, recommended > 2x10
6 
cells/ml. Type 2 - 300RPM, one direction, recommended 
>3x10
6 
cells/ml. Type 3 – 300RPM, change of direction, recommended > 4x106 cells/ml. 
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Figure 2 Suitability of TransAct for activation, transduction and expansion of PBMCs 
in small-scale experiments.  (A-D) PBMCs were activated with either TransAct in 
TexMACS 3% human serum (TA TM3%) or with Dynabeads in X-Vivo 5% human serum 
(D XV5%) and transduced with a CD19-CAR lentivirus after 48 hours. At the end of 9 days, 
cultures were assessed for the mean (A) fold expansion (B) percentage of CD3 T cells 
transduced with CD19-CAR (C) percentage of CD8+CD19-CAR and (D) the absolute CD19-
CAR count, as calculated by % of CD19-CAR+ cells x Final cell count.  Data shown is from 
5 individual healthy controls PBMCs and an unpaired Student’s t test was used to calculate 
data significance whereby  * = p<0.05 
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Figure 3 Automated expansion and transduction of T cells in the CliniMACS Prodigy. 
(A) The expansion of transduced T cells in the CentriCult unit of the CliniMACS Prodigy 
was monitored over a 8 day expansion period for eight independent, healthy donors. The 
processes performed in the GMP facility are shown in red (B) The average fold expansion of 
T cells in the CliniMACS Prodigy was compared to small scale manual controls activated 
under the same conditions as in the CliniMACS Prodigy with TransAct in TexMACS 3% 
human serum (TransAct) or under standard methods of activation using αCD3αCD28 
Dynabeads in X-vivo 5% human serum (Dynabead). (C) Cells were transduced in the 
CliniMACS Prodigy with a CD19-CAR lentiviral vector at an MOI of 5. Transduction of T 
cells was assessed by flow cytometry staining for CD3, CD4, CD8 and FAB staining. Gates 
were set on mock-transduced cells that were expanded in parallel. (D) The percentage of 
automated CD19-CAR transduction was compared to cells transduced in small scale controls.  
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Figure 4 Phenotype and functionality of T cells activated, transduced and expanded in 
the CliniMACS Prodigy. (A-D) Immunophenotyping. At the end of the process, the 
phenotype of cells expanded in the CliniMACS Prodigy or in manual processes was assessed 
by flow cytometry to identify the percentage of (A) lymphocytes (CD45+), T cells ( CD3+), 
Monocytes (CD14+), B Cells (CD20+), NK cells (CD3-CD56+) and NKT cells 
(CD3+CD56+); (B) CD3+CD8+ T cells and (C) the total PD-1 expression on expanded T 
cells. (D) The percentage of memory T cell markers on cells expanded in the CliniMACS 
Prodigy. Results shown as mean ± SD for three independent healthy donors (n=3). (E+F) 
Functionality. (E) Cytokine production of CAR19 T cells when co-cultured with CD19+ 
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SupT1 target cells as measured by CBA. Results are shown for 6 TCT-processes, not 
including 15-01 or 15-04 where small scale control cells were unavailable. (F) Cytotoxic 
activity. Killing efficiency was measured in a 
51
Cr-release assay with CD19-positive SupT1 
target cells in increasing effector-to-target ratios (E:T ratios) post NK-cell depletion. Results 
for 8 TCT-processes are shown as mean ± SEM from triplicates. 
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Figure 5 Anti-tumour effect of automatically manufactured CD19-CAR T cells 
(a) Schematic of mouse model. CD19+ Raji cells expressing Luciferase were injected into 
NSG mice and tumour engraftment monitored on d1. On d2, CAR19 T cells and the 
respective non-transduced controls were injected and tumour growth assessed on d6, d9 and 
d13. (b) IVIS imaging post tumour injection at d1 (top row) and d13 with CAR19 T cells at 
d13 (bottom row, 5 mice on the right). Whereas non-transduced cells did not show anti-
tumour activity, CAR19 T cells cleared the CD19+-tumour in vivo. Representative pictures 
for 5 different manufacturing processes shown. Additional data can be found in the 
supplementary figures.   
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Table 1 Summary of automated manufacturing of CAR19 T cells 
 
 
  
Run 
Yield 
Total lymph 
(x10
8
) 
% CAR19+   
T cells 
Yield  
CAR19 +  
T cells (x10
8
) 
Target met *
/
** 
(≥ 3.5x10
8
 
CAR19+ T cells) 
Length 
of 
Process 
(Days) 
15-01 4.00 23.9 0.96 X 10 
15-03 8.08 44.5 3.6  9  
15-04 23.2 27.5 6.4  9  
15-06 18.5 50.2 9.3  8  
15-07 17.1 56.7 9.7  8  
15-GMP-01 20.0 66.4 13.3  8 
15-GMP-02 18.6 57.4 10.7  8 
15-GMP-03 17.1 54.0 9.2  8 
mean 15.8 ±6.4 x108 47.6 ± 14.9% 7.9 ±4.0 x108   
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Supplementary Figures 
 
 
Figure S1. Gating Strategy for Memory T cell populations.  
Memory T cell populations were analysed by gating on lymphocytes based on their FSC-
A/SSC-A profile and excluding any doublets. Memory T cell populations were assessed by 
their expression of CD45RA, CD62L and CD95 as follows: CD45RA+CD62L- – TEMRA, 
CD45RA+CD62L+CD95- – TNAIVE, CD45RA+CD62L+CD95+ – TSCM, CD45RA-
CD62L+ – TCM and CD45RA-CD62L- – TEM. All FACS gates were set on cells of the 
same donor stained prior to activation on D0 as shown.  
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Figure S2. Transduction with CD19-CAR lentiviral vector does not effect the memory  
T cell compartment.  
The total lymphocyte populations, based on their FSC-A/SSC-A profile, were gated on 
transduced CD19-CAR+ or untransduced CD19-CAR-T cells. The memory T cell 
compartment were assessed based on expression of CD45RA, CD62L and CD95 in Figure 
S2. Results shown are from 8 TCT processes on the CliniMACS Prodigy. 
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Figure S3. Negative control for cytokine release assay measured by CBA. 
 CAR19+ T cells manufactured as described were co-cultured with CD19- SUPT1 cells and 
cytokine release in the cell supernatant was measured by CBA assay. Results shown are from 
6 TCT process excluding donors 15-01 and 15-04. 
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Figure S4. Negative control for cytotoxicity assay. 
Killing efficiency was measured in a 51Cr-release assay with CD19-negative SupT1 target 
cells in increasing effector-to-target ratios (E:T ratios) post NK-cell depletion. Results for 8 
TCT-processes are shown as mean ± SEM from triplicates. 
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Figure S5 Complete IVIS imaging of in vivo model.  
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Figure S6. Tumour Engraftment post CD19-CAR T Therapy  
Tumour engraftment was assessed by flow cytometry analysis of Raji tumour present in the 
bone marrow 11 days post T cell transfer. Tumours were identified based on expression of 
tumour markers CD20 and CD38.  
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Table S1. Hands-on time during the TCT process  
Day of 
procedure Action Steps in detail Hands-on time 
-1 Preparations − Installation of Tubing Set  45 min 
0 Start of run 
− Preparation and connection of media 
− Preparation and connection of activation reagent  
− Connection of cells 
− Programming of activity matrix 
90-120 min 
1 Transduction 
− Preparation of vector and connection to the 
machine 
− Start Transduction (10min) 
30 min 
2 -    
3 Sampling − Start sampling and detach sampling pouch 10 min 
4 Sampling − Start sampling and detach sampling pouch 10 min 
5 
Sampling 
Culture Wash 
− Start sampling and detach sampling pouch 
− Start Culture Wash (confirmation only) 15 min 
6 Sampling − Start sampling and detach sampling pouch 10 min 
7 Sampling − Start sampling and detach sampling pouch 10 min 
8 Sampling − Start sampling and detach sampling pouch 10 min 
9 Sampling End of culture 
− Prepare  and connect formulation buffer 
− Start harvest (45 min) 
− Detach Target Cell bag 
− De-install Tubing Set 
120 min + freezing 
time  
Total Hands on Time 6hrs 20 mins 
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